118 related articles for article (PubMed ID: 9690455)
1. Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
Liu J; Finke J; Krauss JC; Shu S; Plautz GE
Cancer Immunol Immunother; 1998 Jul; 46(5):268-76. PubMed ID: 9690455
[TBL] [Abstract][Full Text] [Related]
2. Specific immunotherapy with tumour-draining lymph node cells cultured with both anti-CD3 and anti-CD28 monoclonal antibodies.
Harada M; Okamoto T; Omoto K; Tamada K; Takenoyama M; Hirashima C; Ito O; Kimura G; Nomoto K
Immunology; 1996 Mar; 87(3):447-53. PubMed ID: 8778032
[TBL] [Abstract][Full Text] [Related]
3. CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and protein-tyrosine kinases p56lck and p59fyn.
Burgess KE; Yamamoto M; Prasad KV; Rudd CE
Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9311-5. PubMed ID: 1384049
[TBL] [Abstract][Full Text] [Related]
4. Cross-reactivity of anti-CD3/IL-2 activated effector cells derived from lymph nodes draining heterologous clones of a murine tumor.
Matsumura T; Krinock RA; Chang AE; Shu S
Cancer Res; 1993 Sep; 53(18):4315-21. PubMed ID: 8364926
[TBL] [Abstract][Full Text] [Related]
5. Characterization of p59fyn-mediated signal transduction on T cell activation.
Fusaki N; Semba K; Katagiri T; Suzuki G; Matsuda S; Yamamoto T
Int Immunol; 1994 Aug; 6(8):1245-55. PubMed ID: 7981151
[TBL] [Abstract][Full Text] [Related]
6. Age-related impairment of p56lck and ZAP-70 activities in human T lymphocytes activated through the TcR/CD3 complex.
Fülöp T; Gagné D; Goulet AC; Desgeorges S; Lacombe G; Arcand M; Dupuis G
Exp Gerontol; 1999 Apr; 34(2):197-216. PubMed ID: 10363787
[TBL] [Abstract][Full Text] [Related]
7. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2.
Yoshizawa H; Chang AE; Shu S
J Immunol; 1991 Jul; 147(2):729-37. PubMed ID: 1830072
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor.
Arca MJ; Krauss JC; Aruga A; Cameron MJ; Shu S; Chang AE
Cancer Gene Ther; 1996; 3(1):39-47. PubMed ID: 8785710
[TBL] [Abstract][Full Text] [Related]
9. Contribution of p56lck to the upregulation of cytokine production and T cell proliferation by IL-2 in human CD3-stimulated T cell clones.
Eljaafari A; Dorval I; Soula M; Quelvennec E; Pirenne H; Fagard R; Sterkers G
Cell Immunol; 1995 Jan; 160(1):152-6. PubMed ID: 7842481
[TBL] [Abstract][Full Text] [Related]
10. Generation of T-cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases.
Geiger JD; Wagner PD; Cameron MJ; Shu S; Chang AE
J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):153-65. PubMed ID: 8471590
[TBL] [Abstract][Full Text] [Related]
11. Increase in the specific activity of p50csk in proliferating T cells correlates with decreased specific activity of p56lck and p59fyn and reduced phosphorylation of CD3 subunits.
Orchansky PL; Ng DH; Johnson P; Teh HS
Mol Immunol; 1996 Apr; 33(6):531-40. PubMed ID: 8700169
[TBL] [Abstract][Full Text] [Related]
12. Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.
Inoue M; Plautz GE; Shu S
Cancer Res; 1996 Oct; 56(20):4702-8. PubMed ID: 8840987
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of protein tyrosine kinases p56lck and p59fyn, and altered tyrosine phosphorylation in murine AIDS.
Trebak M; Lambert CA; Rahmouni S; Greimers R; Boniver J; Moutschen M
Int Immunol; 1998 Oct; 10(10):1473-80. PubMed ID: 9796914
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
[TBL] [Abstract][Full Text] [Related]
15. Interactions between the tyrosine kinases p56lck, p59fyn and p50csk in CD4 signaling in T cells.
Baldari CT; Di Somma MM; Milia E; Bergman M; Telford JL
Eur J Immunol; 1995 Apr; 25(4):919-25. PubMed ID: 7737294
[TBL] [Abstract][Full Text] [Related]
16. T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity.
Levey DL; Srivastava PK
J Exp Med; 1995 Oct; 182(4):1029-36. PubMed ID: 7561676
[TBL] [Abstract][Full Text] [Related]
17. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
18. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present.
Wang Q; Stanley J; Kudoh S; Myles J; Kolenko V; Yi T; Tubbs R; Bukowski R; Finke J
J Immunol; 1995 Aug; 155(3):1382-92. PubMed ID: 7636203
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4.
Krauss JC; Strome SE; Chang AE; Shu S
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530
[TBL] [Abstract][Full Text] [Related]
20. p56Lck and p59Fyn regulate CD28 binding to phosphatidylinositol 3-kinase, growth factor receptor-bound protein GRB-2, and T cell-specific protein-tyrosine kinase ITK: implications for T-cell costimulation.
Raab M; Cai YC; Bunnell SC; Heyeck SD; Berg LJ; Rudd CE
Proc Natl Acad Sci U S A; 1995 Sep; 92(19):8891-5. PubMed ID: 7568038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
